Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ADMA Biologics Inc (ADMA) vs Weibo Corp (WB) Price & Performance

ADMA Biologics IncTrade
Weibo CorpTrade

Price performance (Past 24H)

Key statistics

ADMA Biologics Inc vs Weibo Corp — how do they compare? ADMA Biologics Inc trades at $9.91 (market cap $2.22B), while Weibo Corp trades at $7.74 (market cap $1.93B). The key difference: ADMA Biologics Inc is the larger of the two by market cap, and Weibo Corp pays a 7.75% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.

ADMAWB
Market Cap
$2.22B$1.93B
Sector
HealthMedia
52-Week High
$20.38$12.83
52-Week Low
$7.60$7.20
Enterprise Value
$2.29B$1.20B
Dividend Yield
7.75%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ADMA Biologics Inc

ADMA trades at $9.87, up 1.23% today, with a bullish technical signal supported by moving averages. The company reported strong 2025 fundamentals, including $510.17M revenue, 32.98% net income margin, and robust profitability metrics like 41.9% ROE. However, recent Q1 and Q2 2026 earnings missed expectations, and the stock faces significant negative sentiment due to multiple class-action lawsuits alleging securities fraud, with deadlines in August 2026.

The outlook is mixed: strong fundamentals and an 88.89% analyst buy rating support upside, but legal overhangs and earnings misses pose near-term risks. Investors should weigh solid financial health against potential volatility from litigation outcomes and execution consistency.

Weibo Corp

Weibo (WB) trades at $7.98, up 0.5% with neutral technical signals. The stock shows compelling valuation metrics including a P/E of 5.5 and P/B of 0.5, trading below balance sheet value. Recent quarters show earnings misses but strong profitability with 21.15% net margin. Cash flow trends improved in 2025 with $408M net inflow, while revenue remains stable at $1.76B.

WB presents value opportunity with deep discount to fundamentals, though competitive pressures and recent earnings misses warrant caution. Analyst consensus leans bullish with 45% buy ratings, but structural challenges in user engagement and AI monetization create headwinds. The 8% dividend yield provides downside protection while investors await growth catalysts.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About ADMA Biologics Inc

ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.

Read more on ADMA

About Weibo Corp

Weibo is the largest social media platform in China. As of 2020, Weibo had 521 million monthly active users and 225 million daily active users, many of whom are drawn there by the millions of key opinion leaders in entertainment, sports, and business circles. Sina is the major shareholder, holding 44.7% of shares and with 70.8% voting power.

Read more on WB